1. Home
  2. PFO vs GNLX Comparison

PFO vs GNLX Comparison

Compare PFO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

PFO

Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

N/A

Current Price

$9.02

Market Cap

118.6M

Sector

Finance

ML Signal

N/A

Logo Genelux Corporation

GNLX

Genelux Corporation

N/A

Current Price

$2.52

Market Cap

123.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PFO
GNLX
Founded
1991
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.6M
123.1M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
PFO
GNLX
Price
$9.02
$2.52
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$17.25
AVG Volume (30 Days)
26.0K
330.7K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
6.51%
N/A
EPS Growth
N/A
9.47
EPS
N/A
N/A
Revenue
N/A
$8,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.85
$2.29
52 Week High
$9.90
$8.54

Technical Indicators

Market Signals
Indicator
PFO
GNLX
Relative Strength Index (RSI) 44.33 39.01
Support Level $8.98 $2.33
Resistance Level $9.24 $2.97
Average True Range (ATR) 0.06 0.16
MACD 0.00 -0.01
Stochastic Oscillator 30.97 4.40

Price Performance

Historical Comparison
PFO
GNLX

About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Share on Social Networks: